知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

1102 条记录 (耗时 0.05 秒)

    Anti-CD33 antibodies and uses thereof
    8.
    发明授权
    Anti-CD33 antibodies and uses thereof 有权

    公开(公告)号：US12116406B2

    公开(公告)日：2024-10-15

    申请号：US16617445

    申请日：2018-05-25

    申请人： Fred Hutchinson Cancer Center

    发明人： Roland B. Walter ,  Christopher Mehlin ,  George S. Laszlo ,  Colin E. Correnti

    IPC分类号： C07K16/30 ,  A61P35/02 ,  C07K16/28 ,  C07K16/46

    CPC分类号： C07K16/2803 ,  A61P35/02 ,  C07K2317/31 ,  C07K2317/73 ,  C07K2317/92

    摘要： Anti-CD33 antibodies are described. The anti-CD33 antibodies can bind within the V-set Ig-like domain or the C2-set Ig-like domain of CD33. Epitopes FIG. 1A on the C2-set Ig-like domain can provide a “pan-binding” site, to which the cognate antibody will bind regardless of whether the CD33 molecule also contains the V-set domain (as in, for example, CD33FL) or not (as in, for example, CD33ΔE2). Alternative epitopes on the C2-set Ig-like domain are accessible for binding if the V-set domain is absent (e.g., as in CD33ΔE2). Antibodies that bind an epitope on the C2-set Ig-like domain (whether they exhibit pan or V-set absent binding) are directed at novel therapeutic targets can increase therapeutic efficacy against CD-33-related disorders. Also described are molecules comprising a binding-competent domain from at least one described anti-CD33 antibody, including scFvs, bi-specific antibody molecules, chimeric antigen receptors, and immunoconjugates. Methods of use are also provided.

    ANTI-CADM1 ANTIBODY
    10.
    发明公开
    ANTI-CADM1 ANTIBODY 审中-公开

    公开(公告)号：US20240317853A1

    公开(公告)日：2024-09-26

    申请号：US18289965

    申请日：2022-05-10

    申请人： The University of Tokyo ,  University of the Ryukyus

    发明人： Kazumi NAKANO ,  Toshiki WATANABE ,  Kouhei TSUMOTO ,  Aki TANABE ,  Yoshiaki TAKAHASHI

    IPC分类号： C07K16/28 ,  A61P35/02

    CPC分类号： C07K16/2803 ,  A61P35/02 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/77

    摘要： It is an object of the present invention to provide an antibody that binds to CADM1 expressed on a cell, wherein the antibody alone is capable of inducing internalization of the antibody and the CADM1 into the cell. Specifically, the present invention relates to an antibody binding to CADM1 (Cell adhesion molecule 1), in which the antibody binds to CADM1 on the surface of a cell and induces internalization of the antibody and the CADM1 into the cell, or an antigen-binding fragment thereof. A representative example of the present antibody is an antibody having heavy chain CDR1 comprising the amino acid sequence as set forth in SEQ ID NO: 1, heavy chain CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 2, heavy chain CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 3, light chain CDR1 comprising the amino acid sequence as set forth in SEQ ID NO: 4, light chain CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 5, and light chain CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 6.